2024 American Academy of Neurology Abstract Website

Disclosures for "Impact of Genetic Susceptibility on Multiple Sclerosis Immune Methylome"

Mr. Giordano has nothing to disclose.
Dr. Needhamsen has nothing to disclose.
Dr. Shchetynsky has nothing to disclose.
Dr. Stridh has nothing to disclose.
Dr. Harroud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Harroud has received research support from National Multiple Sclerosis Society. The institution of Dr. Harroud has received research support from Multiple Sclerosis Society of Canada.
The institution of Dr. Gasperi has received research support from German Federal Ministry of Education and Research . The institution of Dr. Gasperi has received research support from Deutsche Forschungsgemeinschaft . The institution of Dr. Gasperi has received research support from Hertie Foundation .
Mr. Zinevych has nothing to disclose.
Dr. Pääkkönen has received personal compensation for serving as an employee of Veil.ai.
Dr. Lahermo has nothing to disclose.
Sandra D'Alfonso has nothing to disclose.
Dr. Barizzone has nothing to disclose.
Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis.
Dr. Chinni has nothing to disclose.
Prof. Hemmer has received personal compensation in the range of $0-$499 for serving as a Consultant for Vaccitech. Prof. Hemmer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Hemmer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Polpharma. Prof. Hemmer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Prof. Hemmer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergy Care. The institution of Prof. Hemmer has received research support from Regeneron. The institution of Prof. Hemmer has received research support from German Research Foundation. The institution of Prof. Hemmer has received research support from German Ministry for Education and Research. The institution of Prof. Hemmer has received research support from European Commission. Prof. Hemmer has received intellectual property interests from a discovery or technology relating to health care. Prof. Hemmer has received intellectual property interests from a discovery or technology relating to health care.
Dr. Flaskamp has nothing to disclose.
Miss Uibel has nothing to disclose.
Dr. Piehl has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parexel/Chugai. The institution of Dr. Piehl has received research support from UCB. The institution of Dr. Piehl has received research support from Merck KGaA. Dr. Piehl has received personal compensation in the range of $10,000-$49,999 for serving as a member scientific advisory board with Swedish Medical products Agency.
Federica Esposito has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. Federica Esposito has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Federica Esposito has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Federica Esposito has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Federica Esposito has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Federica Esposito has received research support from Italian MS Society. The institution of Federica Esposito has received research support from Italian Ministry of Health. The institution of Federica Esposito has received research support from ERA Net. The institution of Federica Esposito has received research support from European Commission. Federica Esposito has received intellectual property interests from a discovery or technology relating to health care.
Elisabetta Mascia, 3236 has nothing to disclose.
Melissa Sorosina has nothing to disclose.
Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi;. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi- Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Mr. Gustavsen has nothing to disclose.
Dr. Sondergaard has nothing to disclose.
Dr. Oturai has nothing to disclose.
The institution of Prof. Dubois has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Merck, Biogen, BMS, Roche. The institution of Prof. Dubois has received research support from Roche.
Prof. H has nothing to disclose.
The institution of Prof. Berge has received research support from Sanofi.
Dr. Bos has nothing to disclose.
Dr. Villoslada has received personal compensation for serving as an employee of Attune Neuroscience. Dr. Villoslada has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Accure Therapeutics. Dr. Villoslada has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has stock in Attune Neurosciences. Dr. Villoslada has stock in Bionure Investments. Dr. Villoslada has stock in Spiral Therapeutics. Dr. Villoslada has stock in Adhera Health. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from NIH. The institution of Dr. Villoslada has received research support from Department of Defense. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care.
Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merci. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbot. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Roland Liblau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-genzyme. Roland Liblau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Servier. Roland Liblau has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Opinion in Immunology. The institution of Roland Liblau has received research support from Roche. The institution of Roland Liblau has received research support from ARSEP. The institution of Roland Liblau has received research support from Fondation pour la Recherche Médicale. The institution of Roland Liblau has received research support from Population Bio UK, Inc. The institution of Roland Liblau has received research support from ANR.
Beatrice Pignolet has nothing to disclose.
Ingrid Kockum has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. The institution of Ingrid Kockum has received research support from Swedish Research council. The institution of Ingrid Kockum has received research support from National MS society. The institution of Ingrid Kockum has received research support from EU Horizon 2020.
Prof. Beck has nothing to disclose.
Prof. Saarela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Prof. Saarela has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Prof. Saarela has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for VEIL.AI. Prof. Saarela has stock in VEIL.AI. The institution of Prof. Saarela has received research support from EU Horizon 2020 program. The institution of Prof. Saarela has received research support from NovoNordisk. The institution of Prof. Saarela has received research support from Nordforsk. The institution of Prof. Saarela has received research support from Sanofi.
The institution of Prof. Jagodic has received research support from Swedish Research Council. The institution of Prof. Jagodic has received research support from EU Horizon 2020 (MultipleMS). The institution of Prof. Jagodic has received research support from European Research Council (ERC-CoG).